Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Operating Margin: 2010-2025

Historic Operating Margin for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -7,160.00%.

  • Northwest Biotherapeutics' Operating Margin fell 301406.00% to -7,160.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -6,927.32%, marking a year-over-year decrease of 297049.00%. This contributed to the annual value of -4,812.45% for FY2024, which is 193936.00% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Operating Margin stood at -7,160.00% for Q3 2025, which was up 36.53% from -11,281.68% recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Operating Margin high stood at 925.93% for Q4 2021, and its period low was -11,281.68% during Q2 2025.
  • Moreover, its 3-year median value for Operating Margin was -4,616.27% (2025), whereas its average is -5,383.26%.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Operating Margin soared by 37,381,755bps in 2021, and later crashed by 785,737bps in 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Operating Margin (Quarterly) stood at 925.93% in 2021, then slumped by 397,082bps to -3,044.89% in 2022, then tumbled by 35,781bps to -3,402.70% in 2023, then crashed by 460,553bps to -8,008.23% in 2024, then tumbled by 301,406bps to -7,160.00% in 2025.
  • Its Operating Margin stands at -7,160.00% for Q3 2025, versus -11,281.68% for Q2 2025 and -4,616.27% for Q1 2025.